Bioavailability dissolution and

Zhang Y, WJ Maier, RM Miller (1997) Effect of rhamnolipids on the dissolution, bioavailability and biodegradation of phenanthrene. Environ Sci Technol 31 2211-2217. 

H. M. Abdou, Dissolution, Bioavailability, and Bioequivalence, Mack Pub., Easton, 1989. 

Abdou, H.M. Dissolution, Bioavailability and Bioequivalence Mack Pubhshing Company Easton, PA, 1989. 

Abdou HM. Dissolution, Bioavailability and Bioequivalence. Easton, PA Mack Publishing Company, 1989. 

It should therefore not be surprising that for relatively small-scale operations involving solids handling within the fine and intermediate chemicals industry, batch operation is preferred. Similarly, continuous processes that involve precipitation or crystallization, a common unit operation in fine chemicals, are rare. Small-scale examples are known, for instance, a continuous crystallization process was used by Bristol-Myres Squibb in order to improve dissolution rates and bioavailability of the product [12]. The above does indicate that not all process or parts thereof are suited for conversion from B2C, given the current technology. 

The effect of particle size reduction on the bioavailability of nitrofurantoin was shown in Fig. 4. The microcrystalline form (< 10 pm) is more rapidly and completely absorbed from the tablet dosage form than is the macrocrystalline form (74-177 pm) from the capsule dosage form. This is not a completely satisfactory illustration of the effect of particle size on the rate and extent of availability, since other manufacturing variables have not been held constant. Nevertheless, it does suggest some correlation between particle size, dissolution rate, and rate of availability. 

The information requirements for products such as prolonged-release oral dosage forms will depend on whether or not it has been possible, during the development of the product, to establish an in vivo-in vitro correlation between clinical data and dissolution studies. In vivo-in vitro correlations should be attempted using product at different stages of development, but bioavailability and pharmacokinetics data from pivotal clinical studies using at least pilot-scale production materials and possibly routine production material are particularly important. Where it is not possible to establish an in vivo-in vitro correlation, additional data will be required to compare the bioavailability of product developed at laboratory scale, pilot scale, and production scale. In the absence of an in vivo-in vitro correlation, the dissolution test will be a quality control tool rather than a surrogate marker for in vivo performance of the product. 

BCS Class II Low-solubility, high-permeability drugs. The bioavailability of products containing these compounds is likely to be dissolution-rate limited. For this reason, a correlation between in vivo bioavailability and in vitro dissolution rate (IVIVC) may be observed. 

Crison, G. L. Amidon. pH and surfactant-facilitated in vitro solubilization and dissolution of ketoprofen, a class II drug. Implications for waiver of bioavailability and bioequivalence studies (Unpublished). 

The absorption of class III drugs is limited by their permeability over the intestinal wall. Thus, as this process is not at all modeled by the classical in vitro dissolution test, no IVIVC should be expected. When drug dissolution becomes slower than gastric emptying, a reduction in the extent of bioavailability will be found in slower dissolution rates as the time when the drug is available for permeation over the gut wall in the small intestine will then be reduced. Thus, the same type of relationship can be expected between bioavailability and in vitro dissolution, as shown in Fig. 21.12 for a class I drug. 

This volume gives an overview of the current status and an outlook to future more reliable predictive approaches. It is subdivided in five sections dealing with studies of membrane permeability and oral absorption, drug dissolution and solubility, the role of transporters and metabolism in oral absorption, computational approaches to drug absorption and bioavailability, and finally with certain drug development issues. 

In recent years, with growing concern about the relative bioavailabilities of different samples of the same drug substance, polymorphism has become of prime interest. Miyazaki and co-workers (23) have reported the existence of two crystalline forms of CTC-HCl. The X-ray powder diffraction patterns, IR spectra, dissolution behaviors, and hygroscopicities that they reported were distinctly different and there were discrepancies in the bioavailabilities. 

Polymorphism is critically important in the design of new drug API [9] and affects a number of areas. The main impact is to the bioavailability and release profile of a drug substance into the body. This is due to differences in solubility and dissolution rate, between the polymorphs. The chemical and physical stability of the formulated drug substance is also dependent on the polymorphic form. Patented registration of all discovered forms and their manufacturing conditions is an important element in protecting a pharmaceutical companies intellectual property. 

Schirmer RE, Kleber JW, Black HR. Correlation of dissolution, disintegration, and bioavailability of aminosalicylic acid tablets. J Pharm Sci 1973 62 1270-1274. 

---